AJP - Heart AJP citation statistics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 276: H1927-H1934, 1999;
0363-6135/99 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, T.
Right arrow Articles by Yokoyama, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, T.
Right arrow Articles by Yokoyama, M.
Vol. 276, Issue 6, H1927-H1934, June 1999

Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells

Tomosaburo Takahashi1, Takahiro Taniguchi1, Hiroaki Konishi2, Ushio Kikkawa2, Yuichi Ishikawa3, and Mitsuhiro Yokoyama1

1 Department of Internal Medicine, First Division, and 3 Faculty of Health Science, Kobe University School of Medicine, Kobe 650; and 2 Biosignal Research Center, Kobe University, Kobe 657, Japan


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Involvement of Akt/Protein kinase B (PKB), a serine/threonine kinase with a pleckstrin-homology domain, in angiotensin II (ANG II)-induced signal transduction was investigated in cultured vascular smooth muscle cells (VSMC). Stimulation of the cells with ANG II led to a marked increase in the kinase activity of Akt/PKB, which coincided with Ser-473 phosphorylation. ANG II-stimulated Akt/PKB activation was rapid, concentration dependent, and inhibited by the AT1-receptor antagonist CV-11974, but not by pertussis toxin. Akt/PKB activity was stimulated by the Ca2+ ionophore ionomycin, suggesting the possible involvement of Ca2+ in ANG II-stimulated Akt/PKB activation. However, blockade of Ca2+ mobilization by BAPTA-AM only partially inhibited ANG II-stimulated Akt/PKB activation. ANG II-stimulated Akt/PKB activation was inhibited by the tyrosine kinase inhibitors genistein and herbimycin A and by the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY-294002. These results indicate that ANG II stimulates Akt/PKB activity via AT1 receptors in VSMC and that the activities of tyrosine kinase and PI3K are required for this activation.

angiotensin II type 1 receptor; signal transduction; vascular biology


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

ANGIOTENSIN II (ANG II) is the main peptide hormone of the renin-angiotensin system and plays an key regulatory role in the regulation of blood pressure and circulating volume. In addition, ANG II has been known to play an important role in the development of various cardiovascular diseases characterized by the accumulation of vascular smooth muscle cells (VSMC), such as hypertension, atherosclerosis, and restenosis after balloon angioplasty (19). Recent evidence suggests that the regulation of not only cell growth but also cell death by apoptosis could be an important determinant of vessel structure and lesion formation (6, 18, 21, 25). In a cell culture system, ANG II stimulates hypertrophic growth and migration of VSMC (19). Moreover, ANG II is a potent antiapoptotic factor capable of reversing the apoptotic effects of serum withdrawal and nitric oxide (46). However, molecular mechanisms responsible for growth promoting and antiapoptotic actions of ANG II have not been fully understood.

ANG II acts via a high-affinity cell-surface receptor called the ANG II type 1 (AT1) receptor. This receptor is a heterotrimeric G protein-coupled receptor with seven transmembrane helices and has been reported to be coupled to either a pertussis toxin-insensitive G protein of the Gq subfamily or a pertussis toxin-sensitive G protein of the Gi subfamily (19). However, some of the intracellular signals mediated by the AT1 receptor are similar to the signaling pathways activated by receptor tyrosine kinases such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. For instance, ANG II induces the activation of the ras protooncogene product Ras (13, 45, 49), the tyrosine and threonine phosphorylation and activation of mitogen-activated protein (MAP) kinases (56), the expression of early growth-response genes such as c-fos, c-jun, and c-myc (28, 40, 41, 53), and the tyrosine phosphorylation of multiple intracellular proteins, including the focal adhesion-associated protein paxillin, focal adhesion kinase, and the Crk-associated substrate p130Cas (36, 44, 52, 57, 58). Recently, phosphatidylinositol 3-kinase (PI3K) has also been shown to be activated in response to ANG II in VSMC (48). Although the role of PI3K in intracellular signaling is underscored by its implication in a plethora of biological responses, relatively little is known about the downstream elements of PI3K.

Akt/protein kinase B (PKB), also called RAC (related to A and C)-protein kinase, is a serine/threonine kinase that contains a pleckstrin-homology domain in its NH2-terminal end region and a catalytic domain closely related to both cAMP-dependent protein kinase and protein kinase C (PKC), and it is also the cellular homolog of the product of the retroviral oncogene v-akt (4, 8, 26). Kinase activity of Akt/PKB has been shown to be stimulated by growth factors acting through receptor tyrosine kinases such as PDGF, EGF, and insulin receptors, and the activation of Akt/PKB by these growth factors has been shown to be mediated by PI3K (7, 9, 16, 31). Recently, a signaling pathway from PI3K to Akt/PKB was implicated in some cellular responses of PI3K including a protection from apoptosis (12, 27, 29, 34). However, little is yet known about the participation of Akt/PKB in signaling pathways for seven-transmembrane G protein-coupled receptors, especially for G proteins of the Gq subfamily-coupled receptors.

In the present study, we first examined whether Akt/PKB activity was stimulated in response to ANG II in VSMC. This report shows that, via AT1 receptors, ANG II stimulates the kinase activity and Ser-473 phosphorylation of Akt/PKB in a pertussis toxin-insensitive fashion in VSMC. Evidence is also provided showing that the activities of tyrosine kinase and PI3K are required for this activation. These results suggest that Akt/PKB could play a role in ANG II-induced signal transduction in VSMC.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Materials. ANG II, ionomycin, phorbol 12-myristate 13-acetate (PMA), pertussis toxin, and wortmannin were obtained from Sigma (St. Louis, MO). 1,2-Bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester (BAPTA-AM) and herbimycin A were from Life Technologies (Rockville, MD). LY-294002 and genistein were from Calbiochem (San Diego, CA). The sheep polyclonal antibody against Akt/PKB was from Upstate Biotechnology (Lake Placid, NY). The rabbit polyclonal phospho-specific Akt/PKB antibody, which detects Akt/PKB only when phosphorylated at Ser-473, and total Akt/PKB antibody were from New England Bio Labs (Beverly, MA). Protein G-Sepharose 4 Fast Flow was from Pharmacia Biotech (Uppsala, Sweden). The AT1-receptor antagonist CV-11974 and the AT2-receptor antagonist PD-123319 were gifts from Takeda Pharmaceutical (Osaka, Japan) and Parke-Davis (Ann Arbor, MI), respectively. Other materials and chemicals were obtained from commercial sources.

Cell culture. VSMC were isolated from rat thoracic aortas by enzymatic dissociation and characterized as described previously (32). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, and 100 µg/ml streptomycin as described previously (51, 52). For experiments, cells between passage levels 6 and 16 were made quiescent by incubation with serum-free DMEM for 48 h before use.

Preparation of cell lysates and immunoprecipitation kinase assay. The quiescent VSMC were stimulated as indicated. The cells were then washed twice with ice-cold phosphate-buffered saline and lysed into buffer A (50 mM Tris · HCl, pH 7.5, 0.1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 50 mM sodium fluoride, 10 mM sodium beta -glycerol phosphate, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, and 0.1% 2-mercaptoethanol) containing 1 µM microcystin LR (Research Biochemicals International). After insoluble materials were removed by centrifugation at 15,000 rpm for 20 min, protein concentrations in the supernatants were normalized using a protein assay (Bio-Rad). As whole cell extracts, lysates were directly added to 5× sample buffer (1:4 vol/vol) for SDS-polyacrylamide gel electrophoresis (PAGE) and boiled at 100°C for 5 min. For immunoprecipitation, after the lysates (500 µg total protein) were preabsorbed with 15 µl of a 1:1 slurry of protein G-Sepharose for 30 min at 4°C, the lysates were incubated with sheep polyclonal anti-Akt/PKB antibody (2 µg) for 2 h at 4°C. Immunocomplexes were immunoprecipitated for 1 h at 4°C with 40 µl of the 1:1 slurry of protein G-Sepharose. The immunocomplexes were washed three times with buffer A containing 500 mM NaCl, twice with buffer B (50 mM Tris · HCl, pH 7.5, 0.03% Brij 35, 0.1 mM EGTA, and 0.1% 2-mercaptoethanol), and once with assay dilution buffer (20 mM MOPS, pH 7.2, 25 mM sodium beta -glycerol phosphate, 1 mM sodium orthovanadate, and 1 mM dithiothreitol). The beads were resuspended in 30 µl of kinase reaction mixture [assay dilution buffer containing 25 mM MgCl2, 170 µM ATP, 1 µg histone H2B (Boehringer Mannheim), and 1 µCi [gamma -32P]ATP] and incubated at 30°C for 30 min. Kinase reactions were stopped by the addition of 7 µl of 5× sample buffer, after which the samples were boiled for 5 min at 100°C and electrophoresed on 15% SDS-polyacrylamide gels. The gels were stained with Coomassie blue, and dried, and radioactivities were analyzed using a bio-imaging analyzer (Fujix BAS2000).

Immunoblot analysis. Samples were subjected to 10% SDS-PAGE, and the separated proteins were electrophoretically transferred to polyvinylidene difluoride membranes (Millipore). Blots were incubated with rabbit polyclonal phospho-specific Akt/PKB antibody or total Akt/PKB antibody, and the primary antibodies were detected using horseradish peroxidase-labeled donkey anti-rabbit IgG, followed by enhanced chemiluminescence (Amersham Life Science).

Statistical analysis. Where applicable, results were expressed as means ± SE. Statistical analysis was performed with unpaired Student's t-test or ANOVA when appropriate, and differences were considered to be significant when the probability value was <0.05.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Effects of ANG II and PDGF on kinase activity and Ser-473 phosphorylation of Akt/PKB in VSMC. To examine the effect of ANG II on kinase activity of Akt/PKB, cultured VSMC were treated with either ANG II (100 nM) or PDGF BB homodimer (PDGF-BB; 20 ng/ml), and kinase activity of Akt/PKB was measured by immunoprecipitation kinase assay with histone H2B as a substrate. As shown in Fig. 1, A and B, stimulation of the cells with ANG II led to a marked increase in the kinase activity of Akt/PKB. As has already been reported in other cell types (16), PDGF also stimulated kinase activity of Akt/PKB in VSMC, and this activation was more pronounced than that by ANG II. Because Akt/PKB has been shown to be activated by phospholipid binding and by phosphorylation within the activation loop at Thr-308 and within the COOH terminus at Ser-473 (22, 23), we assessed the effect of ANG II on the phosphorylation state of Akt/PKB at Ser-473 by immunoblotting with phospho-specific Akt/PKB antibody that recognized Akt/PKB only when phosphorylated at Ser-473. Stimulation of VSMC with ANG II or PDGF caused a marked increase in the phosphorylation state at Ser-473, whereas total Akt/PKB proteins were not altered by treatment with ANG II or PDGF (Fig. 1C). These results indicate that, in VSMC, ANG II stimulates the kinase activity of Akt/PKB and that this activation is coincident with Ser-473 phosphorylation.


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 1.   Effects of ANG II and platelet-derived growth factor (PDGF) on kinase activity and Ser-473 phosphorylation of Akt/protein kinase B (PKB) in vascular smooth muscle cells (VSMC). Cultured VSMC were treated with or without 100 nM ANG II or 20 ng/ml PDGF BB homodimer for 5 min. Cell extracts were immunoprecipitated with anti-Akt/PKB polyclonal antibody (Ab). A: anti-Akt/PKB immunoprecipitates were subjected to in vitro kinase assay with histone H2B as a substrate. B: radioactivities of phosphorylated histone H2B were quantitated and plotted as percentages of unstimulated levels. Values are means ± SE of 3 independent trials. * P < 0.05. C: whole cell extracts were analyzed by immunoblotting with phospho-specific Akt/PKB antibody or total Akt/PKB antibody. Experiment represents 1 of 3 independent trials that gave nearly identical results.

Time course and dose response of ANG II- and PDGF-stimulated kinase activity of Akt/PKB. The effects of ANG II and PDGF on kinase activities of Akt/PKB were time and concentration dependent. ANG II-stimulated Akt/PKB activation could be detected within 2 min after addition of ANG II, reached a maximum at ~5 min, and then declined (Fig. 2A). Half-maximum and maximum effects were achieved at 10 and 100 nM of ANG II, respectively (Fig. 2B). On the other hand, activation of Akt/PKB by PDGF was maximal at 5-10 min and then slowly declined (Fig. 2C) and was dose dependent up to 200 ng/ml (Fig. 2D).


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 2.   Time course and dose response of ANG II- or PDGF-stimulated kinase activity of Akt/PKB. Cultured VSMC were treated with 100 nM ANG II (A) or 20 ng/ml PDGF (C) for various periods of time as indicated or treated for 5 min with various concentrations of ANG II (B) or PDGF (D) as indicated. Insets: anti-Akt/PKB immunoprecipitates were subjected to in vitro kinase assay with histone H2B as a substrate. Radioactivities of phosphorylated histone H2B were quantitated. Values are means ± SE of 3 independent trials and are expressed as percentages of unstimulated levels. Insets are representative of 3 independent trials. * P < 0.05 vs. control.

Effects of AT1- and AT2-receptor antagonists and pertussis toxin on ANG II-stimulated kinase activity of Akt/PKB. ANG II receptors have been classified into AT1 and AT2 subtypes (19). To determine which ANG II receptor subtype mediates Akt/PKB activation, VSMC were pretreated with either the AT1-receptor antagonist CV-11974 or the AT2-receptor antagonist PD-123319. ANG II-stimulated Akt/PKB activation was completely inhibited by CV-11974 (200 nM), but not by PD-123319 (200 nM), whereas both antagonists by themselves had no effect on Akt/PKB activity (Fig. 3). These results indicated that the stimulatory effect of ANG II on Akt/PKB activity was mediated by AT1 receptors. The AT1 receptor has been shown to be linked to a pertussis toxin-insensitive G protein of the Gq subfamily or a pertussis toxin-sensitive G protein of the Gi subfamily (19). Pretreatment with 500 ng/ml of pertussis toxin for 5 h neither affected basal Akt/PKB activity nor inhibited the response to ANG II (Fig. 3). We have previously shown that this protocol of treatment with pertussis toxin resulted in almost complete ADP ribosylation of the alpha -subunit of the G protein of the Gi subfamily in VSMC (45, 55). These results suggest that a G protein of Gq subfamily is involved in this reaction.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 3.   Effects of AT1- and AT2-receptor antagonists and pertussis toxin on ANG II-stimulated kinase activity of Akt/PKB. Cultured VSMC were pretreated with or without 200 nM CV-11974 for 2 min, 200 nM PD-123319 for 2 min, or 500 ng/ml pertussis toxin (PTX) for 5 h. Cells were subsequently treated with or without 100 nM ANG II for 5 min. A: anti-Akt/PKB immunoprecipitates were subjected to in vitro kinase assay using histone H2B as a substrate. Experiment represents 1 of 3 independent trials that gave nearly identical results. B: radioactivities of phosphorylated histone H2B were quantitated. Values are means ± SE of 3 independent trials and are expressed as percentages of unstimulated levels. * P < 0.05 vs. control.

Effects of PMA and ionomycin on kinase activity of Akt/PKB. Via a pertussis toxin-insensitive G protein of the Gq subfamily, the activation of AT1 receptor induces a phospholipase C-mediated phosphoinositide hydrolysis, which causes PKC activation and intracellular Ca2+ mobilization (19). Whereas the activation of PKC by phorbol ester has been reported to have almost no effect on the enzymatic activity of Akt/PKB (16, 31), the involvement of Ca2+ on Akt/PKB activation remains to be elucidated. We next examined whether intracellular Ca2+ mobilization or PKC activation was involved in Akt/PKB activation in VSMC. The Ca2+ ionophore ionomycin (1 µM) significantly stimulated kinase activity of Akt/PKB, whereas the PKC-activating phorbol ester PMA (100 nM) had a minimal effect on Akt/PKB activity (Fig. 4). These results suggested that Ca2+ mobilization was involved in ANG II-stimulated Akt/PKB activation in VSMC.


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 4.   Effects of PMA and ionomycin on kinase activity of Akt/PKB. Cultured VSMC were treated with either 100 nM PMA or 1 µM ionomycin for various periods of time as indicated. A: anti-Akt/PKB immunoprecipitates were subjected to in vitro kinase assay with histone H2B as a substrate. Experiment represents 1 of 3 independent trials that gave nearly identical results. B: radioactivities of phosphorylated histone H2B were quantitated. Values are means ± SE of 3 independent trials and are expressed as percentages of unstimulated levels. * P < 0.05 vs. control.

Effects of BAPTA-AM on kinase activity of Akt/PKB stimulated by ANG II and ionomycin. Next, to assess the involvement of Ca2+ mobilization in ANG II-stimulated Akt/PKB activation, we examined the effect of the membrane-permeable Ca2+ chelator BAPTA-AM on ANG II-stimulated Akt/PKB activation. The blockade of Ca2+ mobilization by BAPTA-AM (25 µM) only partially inhibited ANG II-stimulated Akt/PKB activation (Fig. 5). Under the same conditions, pretreatment with BAPTA-AM effectively inhibited ionomycin-stimulated Akt/PKB activation, but not basal Akt/PKB activity (Fig. 5), and indeed suppressed ANG II-mediated Ca2+ mobilization in these cells (data not shown). These results suggest that Ca2+ mobilization was partially involved in ANG II-induced Akt/PKB activation, whereas a Ca2+-independent pathway could also exist.


View larger version (30K):
[in this window]
[in a new window]
  		Fig. 5.   Effects of 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester (BAPTA-AM) on kinase activity of Akt/PKB stimulated by ANG II or ionomycin. Cultured VSMC were pretreated with or without 25 µM BAPTA-AM for 45 min. Cells were subsequently treated with or without 100 nM ANG II or 1 µM ionomycin for 5 min. A: anti-Akt/PKB immunoprecipitates were subjected to in vitro kinase assay with histone H2B as a substrate. Experiment represents 1 of 3 independent trials that gave nearly identical results. B: radioactivities of phosphorylated histone H2B were quantitated. Values are means ± SE of 3 independent trials and are expressed as percentages of unstimulated levels. * P < 0.05 vs. control. § P < 0.05 vs. ANG II-stimulated Akt/PKB activation. # P < 0.05 vs. ionomycin-stimulated Akt/PKB activation.

Effects of tyrosine kinase inhibitors on ANG II-induced Akt/PKB activation. In VSMC, ANG II has been shown to activate the multiple tyrosine kinase pathways that, by analogy with growth factors, are important in mediating the multiple cellular responses of ANG II (5, 20, 57). We next examined whether tyrosine kinase activity was required for ANG II-induced Akt/PKB activation by using the tyrosine kinase inhibitors genistein and herbimycin A. These inhibitors are chemically and mechanically distinct, are highly specific for protein tyrosine kinases (1, 17, 37, 59), and are shown to inhibit ANG II-stimulated overall tyrosine phosphorylation and protein synthesis without affecting ANG II binding to the AT1 receptor, phospholipase C activation, and MAP kinase activation (35, 51). As shown in Fig. 6, both genistein (100 µM) and herbimycin A (3 µM) inhibited activation of Akt/PKB by ANG II, although the inhibitory effect of herbimycin A was less than that of genistein. These inhibitors did not affect the basal kinase activity of Akt/PKB. These results suggest the involvement of tyrosine kinase(s) in ANG II-stimulated Akt/PKB activation.


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 6.   Effects of tyrosine kinase inhibitors on ANG II-induced Akt/PKB activation. Cultured VSMC were incubated with or without 100 µM genistein for 1 h or 3 µM herbimycin A for 16 h before stimulation with 100 nM ANG II for 5 min. A: anti-Akt/PKB immunoprecipitates were subjected to in vitro kinase assay with histone H2B as a substrate. Experiment represents 1 of 3 independent trials that gave nearly identical results. B: radioactivities of phosphorylated histone H2B were quantitated. Values are means ± SE of 3 independent trials and are expressed as percentages of unstimulated levels. * P < 0.05 vs. control. # P < 0.05 vs. ANG II-stimulated Akt/PKB activation.

Effects of PI3K inhibitors on kinase activity of Akt/PKB stimulated by ANG II, PDGF, and ionomycin. PI3K is shown to be necessary and sufficient for growth factor-dependent activation of Akt/PKB, although an additional pathway independent of PI3K for activation of Akt/PKB has been proposed (14, 22, 23). We then tested the effect of two structurally unrelated PI3K inhibitors, wortmannin and LY-294002, on ANG II-induced Akt/PKB activation. Wortmannin is a fungal metabolite that has been characterized as a specific inhibitor of PI3K at nanomolar concentrations (3, 43, 50). LY-294002 is another specific inhibitor of PI3K at low micromolar concentrations, but it has no inhibitory effect against phosphatidylinositol 4-kinase or a number of intracellular serine/threonine or tyrosine kinases at a 50 µM concentration (50, 60). As shown in Fig. 7, both wortmannin (100 nM) and LY-294002 (50 µM) completely inhibited ANG II-stimulated kinase activity of Akt/PKB. These inhibitors also inhibited Akt/PKB activation stimulated by PDGF or ionomycin in VSMC. Moreover, these inhibitors potently reduced the basal kinase activity of Akt/PKB, although the inhibitory effect of wortmannin was not significant. These results indicate that PI3K is involved in not only the AT1 receptor-mediated Akt/PKB activation but also the maintenance of the basal activity of Akt/PKB in VSMC.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 7.   Effects of phosphatidylinositol 3-kinase inhibitors on kinase activity of Akt/PKB stimulated by ANG II, PDGF, or ionomycin. Cultured VSMC were pretreated with or without 50 µM LY-294002 for 15 min or 100 nM wortmannin for 20 min. Cells were subsequently treated with 100 nM ANG II, 20 ng/ml PDGF, or 1 µM ionomycin for 5 min. A: anti-Akt/PKB immunoprecipitates were subjected to in vitro kinase assay with histone H2B as a substrate. Experiment represents 1 of 3 independent trials that gave nearly identical results. B: radioactivities of phosphorylated histone H2B were quantitated. Values are means ± SE of 3 independent trials and are expressed as percentages of unstimulated levels. * P < 0.05 vs. control. § P < 0.05 vs. ANG II-stimulated Akt/PKB activation.  P < 0.05 vs. PDGF-stimulated Akt/PKB activation. # P < 0.05 vs. ionomycin-stimulated Akt/PKB activation.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In the present study, we first demonstrated that ANG II stimulated the kinase activity and Ser-473 phosphorylation of Akt/PKB via G protein-coupled AT1 receptors in VSMC. Little is known regarding the participation of Akt/PKB in signaling pathways for the Gq protein-coupled receptors, and only a few reports have demonstrated the G protein-coupled, receptor-mediated Akt/PKB activation. These reports include the activation by Gi protein-coupled thrombin receptors in platelets (15), Gs and Gi protein-coupled beta 3-adrenoreceptors in adipocytes (39), and Gi protein-coupled receptors in phagocytes (54). In VSMC, ANG II-induced Akt/PKB activation was pertussis toxin insensitive, implying that a G protein of the Gq subfamily is involved in AT1 receptor-mediated Akt/PKB activation. Via a G protein of the Gq subfamily, AT1-receptor activation leads to the production of two second messengers, inositol trisphosphate and diacylglycerol, that induce the release of Ca2+ from intracellular storage and PKC activation. The activity of Akt/PKB was stimulated by the Ca2+ ionophore ionomycin but not by the PKC-activating phorbol ester PMA. These results suggest that Ca2+, but not phorbol ester-responsive PKC, was involved in ANG II-stimulated Akt/PKB activation, although it is still possible that activation of Akt/PKB could occur via atypical PKC, which is not activated by PMA in VSMC (42). However, blockade of Ca2+ mobilization by BAPTA-AM, which effectively inhibited ionomycin-induced Akt/PKB activation, only partially inhibited ANG II-stimulated Akt/PKB activation. These results suggest that both Ca2+-dependent and -independent mechanisms may be involved in ANG II-stimulated Akt/PKB activation in VSMC.

ANG II-stimulated Akt/PKB activation was inhibited by the tyrosine kinase inhibitors genistein and herbimycin A, suggesting that tyrosine phosphorylation may be involved in this process. It has been shown that activated forms of c-Src, v-Src, or SrcY527F activate Akt/PKB in fibroblasts (10) and that ANG II activates c-Src in VSMC (24), suggesting the possible involvement of c-Src in ANG II-induced Akt/PKB activation in VSMC. However, the inhibitory effect of genistein, which is a broad-spectrum inhibitor of tyrosine kinases as well as Src-family tyrosine kinases (1), is more potent than that of herbimycin A, which is a relatively specific inhibitor of Src-family tyrosine kinases (17, 59). Thus the responsible tyrosine kinase(s) for ANG II-stimulated Akt/PKB activation remains obscure.

Growth factors such as PDGF and EGF were reported to activate Akt/PKB, and this growth factor-dependent Akt/PKB activation was shown to be prevented by wortmannin, expression of PDGF-receptor mutants that cannot interact with PI3K, and expression of dominant negative mutants of PI3K (2, 7, 16, 31). On the other hand, expression of a constitutive active mutant of PI3K results in the activation of Akt/PKB (15, 30, 38). Thus PI3K is necessary and sufficient for growth factor-dependent activation of Akt/PKB. However, an additional pathway for activation of Akt/PKB that is independent of PI3K could exist, because cellular stress such as heat shock and hyperosmolarity, beta 3-adrenoreceptor stimulation, and elevation of intracellular cAMP level have been shown to activate Akt/PKB through a pathway independent of PI3K (33, 39, 47). Treatment of VSMC with two structurally unrelated PI3K inhibitors, wortmannin and LY-294002, not only completely inhibited ANG II-stimulated activation of Akt/PKB but also reduced the basal kinase activity of Akt/PKB. These results indicate that PI3K activity is necessary for both ANG II-stimulated activation of Akt/PKB and maintenance of basal Akt/PKB kinase activity in VSMC. Furthermore, Akt/PKB activation by PDGF or ionomycin was significantly inhibited by these inhibitors, although there existed a small degree of increase by PDGF in Akt/PKB activity in wortmannin-treated cells. These results indicate a predominant role of PI3K in both PDGF- and ionomycin-induced Akt/PKB activation in VSMC, whereas it is possible that a wortmannin-insensitive mechanism may be partially involved in PDGF-induced Akt/PKB activation.

At present, the exact role of Akt/PKB in ANG II action is unclear. It is becoming apparent that Akt/PKB plays various roles in cell regulation, including growth-factor-induced survival and growth promotion (11, 22). Therefore, it is possible that ANG II-stimulated Akt/PKB activation has a potential role in the processes that regulate VSMC survival and hypertrophy, although we can only speculate at this point.

In summary, the results of the present study provide the first demonstration of a potential role of Akt/PKB in ANG II actions in VSMC. Identification of upstream and downstream elements of Akt/PKB activation will be an important issue in understanding the role of Akt/PKB in ANG II actions and in fully clarifying the signaling pathways of ANG II in VSMC.


    ACKNOWLEDGEMENTS

This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (1998).


    FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Address for reprint requests and other correspondence: T. Taniguchi, Dept. of Internal Medicine (1st Div.), Kobe Univ. School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan (E-mail: taniguch{at}med.kobe-u.ac.jp).

Received 21 September 1998; accepted in final form 24 February 1999.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Akiyama, T., J. Ishida, S. Nakagawa, H. Ogawara, S. Watanabe, N. Itoh, M. Shibuya, and Y. Fukami. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262: 5592-5595, 1987[Abstract/Free Full Text].

2.   Andjelkovic, M., T. Jakubowicz, P. Cron, X. F. Ming, J. W. Han, and B. A. Hemmings. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc. Natl. Acad. Sci. USA 93: 5699-5704, 1996[Abstract/Free Full Text].

3.   Arcaro, A., and M. P. Wymann. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296: 297-301, 1993.

4.   Bellacosa, A., J. R. Testa, S. P. Staal, and P. N. Tsichlis. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254: 274-277, 1991[Abstract/Free Full Text].

5.   Berk, B. C., and M. A. Corson. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ. Res. 80: 607-616, 1997[Abstract/Free Full Text].

6.   Bochaton-Piallat, M. L., F. Gabbiani, M. Redard, A. Desmouliere, and G. Gabbiani. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am. J. Pathol. 146: 1059-1064, 1995[Abstract].

7.   Burgering, B. M. T., and P. J. Coffer. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602, 1995[Medline].

8.   Coffer, P. J., and J. R. Woodgett. Molecular cloning and characterization of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. J. Biochem. 201: 475-481, 1991[Medline].

9.   Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995[Medline].

10.   Datta, K., A. Bellacosa, T. O. Chan, and P. N. Tsichlis. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem. 271: 30835-30839, 1996[Abstract/Free Full Text].

11.   Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10: 262-267, 1998[Medline].

12.   Dudek, H., S. R. Datta, T. F. Franke, M. J. Birnbaum, R. Yao, G. M. Cooper, R. A. Segal, D. R. Kaplan, and M. E. Greenberg. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275: 661-665, 1997[Abstract/Free Full Text].

13.   Eguchi, S., T. Matsumoto, E. D. Motley, H. Utsunomiya, and T. Inagami. Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. J. Biol. Chem. 271: 14169-14175, 1996[Abstract/Free Full Text].

14.   Franke, T. F., D. R. Kaplan, and L. C. Cantley. PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-437, 1997[Medline].

15.   Franke, T. F., D. R. Kaplan, L. C. Cantley, and A. Toker. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665-668, 1997[Abstract/Free Full Text].

16.   Franke, T. F., S. I. Yang, T. O. Chan, K. Datta, A. Kazlauskas, D. K. Morrison, D. R. Kaplan, and P. N. Tsichlis. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81: 727-736, 1995[Medline].

17.   Fukazawa, H., P. M. Li, C. Yamamoto, Y. Murakami, S. Mizuno, and Y. Uehara. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro. Biochem. Pharmacol. 42: 1661-1671, 1991[Medline].

18.   Geng, Y. J., and P. Libby. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1beta -converting enzyme. Am. J. Pathol. 147: 251-266, 1995[Abstract].

19.   Griendling, K. K., B. Lassegue, and R. W. Alexander. Angiotensin receptors and their therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 36: 281-306, 1996[Medline].

20.   Griendling, K. K., M. Ushiofukai, B. Lassegue, and R. W. Alexander. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 29: 366-373, 1997[Abstract/Free Full Text].

21.   Han, D. K., C. C. Haudenschild, M. K. Hong, B. T. Tinkle, M. B. Leon, and G. Liau. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am. J. Pathol. 147: 267-277, 1995[Abstract].

22.   Hemmings, B. A. Akt signaling: linking membrane events to life and death decisions. Science 275: 628-630, 1997[Free Full Text].

23.   Hemmings, B. A. PtdIns(3,4,5)P3 gets its message across. Science 277: 534, 1997[Abstract/Free Full Text].

24.   Ishida, M., M. B. Marrero, B. Schieffer, T. Ishida, K. E. Bernstein, and B. C. Berk. Angiotensin II activates pp60c-src in vascular smooth muscle cells. Circ. Res. 77: 1053-1059, 1995[Abstract/Free Full Text].

25.   Isner, J. M., M. Kearney, S. Bortman, and J. Passeri. Apoptosis in human atherosclerosis and restenosis. Circulation 91: 2703-2711, 1995[Abstract/Free Full Text].

26.   Jones, P. F., T. Jakubowicz, F. J. Pitossi, F. Maurer, and B. A. Hemmings. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc. Natl. Acad. Sci. USA 88: 4171-4175, 1991[Abstract/Free Full Text].

27.   Kauffmann-Zeh, A., P. Rodriguez-Viciana, E. Ulrich, C. Gilbert, P. Coffer, J. Downward, and G. Evan. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385: 544-548, 1997[Medline].

28.   Kawahara, Y., M. Sunako, T. Tsuda, H. Fukuzaki, Y. Fukumoto, and Y. Takai. Angiotensin II induces expression of the c-fos gene through protein C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 150: 52-59, 1988[Medline].

29.   Khwaja, A., P. Rodriguez-Viciana, S. Wennstrom, P. H. Warne, and J. Downward. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16: 2783-2793, 1997[Medline].

30.   Klippel, A., C. Reinhard, W. M. Kavanaugh, G. Apell, M. A. Escobedo, and L. T. Williams. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol. Cell. Biol. 16: 4117-4127, 1996[Abstract].

31.   Kohn, A. D., K. S. Kovacina, and R. A. Roth. Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. EMBO J. 14: 4288-4295, 1995[Medline].

32.   Koide, M., Y. Kawahara, T. Tsuda, Y. Ishida, K. Shii, and M. Yokoyama. Endothelin-1 stimulates tyrosine phosphorylation and the activities of two mitogen-activated protein kinases in cultured vascular smooth muscle cells. J. Hypertens. 10: 1173-1182, 1992[Medline].

33.   Konishi, H., H. Matsuzaki, M. Tanaka, Y. Ono, C. Tokunaga, S. Kuroda, and U. Kikkawa. Activation of RAC-protein kinase by heat shock and hyperosmolarity stress through a pathway independent of phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. USA 93: 7639-7643, 1996[Abstract/Free Full Text].

34.   Kulik, G., A. Klippel, and M. J. Weber. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17: 1595-1606, 1997[Abstract].

35.   Leduc, I., P. Haddad, E. Giasson, and S. Meloche. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells. Mol. Pharmacol. 48: 582-592, 1995[Abstract].

36.   Leduc, I., and S. Meloche. Angiotensin II stimulates tyrosine phosphorylation of the focal adhesion-associated protein paxillin in aortic smooth muscle cells. J. Biol. Chem. 270: 4401-4404, 1995[Abstract/Free Full Text].

37.   Levitzki, A., and A. Gazit. Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995[Abstract/Free Full Text].

38.   Marte, B. M., P. Rodriguez-Viciana, S. Wennstrom, P. H. Warne, and J. Downward. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr. Biol. 7: 63-70, 1997[Medline].

39.   Moule, S. K., G. I. Welsh, N. J. Edgell, E. J. Foulstone, C. G. Proud, and R. M. Denton. Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta -adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin-sensitive and -insensitive mechanisms. J. Biol. Chem. 272: 7713-7719, 1997[Abstract/Free Full Text].

40.   Naftilan, A. J., G. K. Gilliland, C. S. Eldridge, and A. S. Kraft. Induction of proto-oncogene c-jun by angiotensin II. Mol. Cell. Biol. 10: 5536-5540, 1990[Abstract/Free Full Text].

41.   Naftilan, A. J., R. E. Pratt, and V. J. Dzau. Induction of platelet-derived growth factor A-chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth muscle cells. J. Clin. Invest. 83: 1419-1424, 1989.

42.   Nishizuka, Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9: 484-496, 1995[Abstract].

43.   Okada, T., L. Sakuma, Y. Fukui, O. Hazeki, and M. Ui. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J. Biol. Chem. 269: 3563-3567, 1994[Abstract/Free Full Text].

44.   Okuda, M., Y. Kawahara, I. Nakayama, M. Hoshijima, and M. Yokoyama. Angiotensin II transduces its signal to focal adhesions via angiotensin II type 1 receptors in vascular smooth muscle cells. FEBS Lett. 368: 343-347, 1995[Medline].

45.   Okuda, M., Y. Kawahara, and M. Yokoyama. Angiotensin II type 1 receptor-mediated activation of Ras in cultured rat vascular smooth muscle cells. Am. J. Physiol. 271 (Heart Circ. Physiol. 40): H595-H601, 1996[Abstract/Free Full Text].

46.   Pollman, M. J., T. Yamada, M. Horiuchi, and G. H. Gibbons. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ. Res. 79: 748-756, 1996[Abstract/Free Full Text].

47.   Sable, C. L., N. Filippa, B. Hemmings, and E. Van Obberghen. cAMP stimulates protein kinase B in a wortmannin-insensitive manner. FEBS Lett. 409: 253-257, 1997[Medline].

48.   Saward, I., and P. Zahradka. Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ. Res. 81: 249-257, 1997[Abstract/Free Full Text].

49.   Schieffer, B., W. G. Paxton, Q. Chai, M. B. Marrero, and K. E. Bernstein. Angiotensin II controls p21ras activity via pp60c-src. J. Biol. Chem. 271: 10329-10333, 1996[Abstract/Free Full Text].

50.   Shepherd, P. R., D. J. Withers, and K. Siddle. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem. J. 333: 471-490, 1998.

51.   Takahashi, T., Y. Kawahara, M. Okuda, H. Ueno, A. Takeshita, and M. Yokoyama. Angiotensin II stimulates mitogen-activated protein kinases and protein synthesis by a Ras-independent pathway in vascular smooth muscle cells. J. Biol. Chem. 272: 16018-16022, 1997[Abstract/Free Full Text].

52.   Takahashi, T., Y. Kawahara, T. Taniguchi, and M. Yokoyama. Tyrosine phosphorylation and association of p130Cas and c-Crk II by ANG II in vascular smooth muscle cells. Am. J. Physiol. 274 (Heart Circ. Physiol. 43): H1059-H1065, 1998[Abstract/Free Full Text].

53.   Taubman, M. B., B. C. Berk, S. Izumo, T. Tsuda, R. W. Alexander, and B. Nadal-Ginard. Angiotensin II induces c-fos mRNA in aortic smooth muscle. J. Biol. Chem. 264: 526-530, 1989[Abstract/Free Full Text].

54.   Tilton, B., M. Andjelkovic, S. A. Didichenko, B. A. Hemmings, and M. Thelen. G-protein-coupled receptors and Fc-receptors mediate activation of Akt protein kinase B in human phagocytes. J. Biol. Chem. 272: 28096-28101, 1997[Abstract/Free Full Text].

55.   Tsuda, T., Y. Kawahara, Y. Fukumoto, Y. Takai, and H. Fukuzaki. Stimulation of phospholipase C-mediated hydrolysis of phosphoinositides by adenosine 5'-triphosphate via P2-purinoceptors in cultured rat aortic vascular smooth muscle cells. Jpn. Circ. J. 52: 570-579, 1988[Medline].

56.   Tsuda, T., Y. Kawahara, Y. Ishida, M. Koide, K. Shii, and M. Yokoyama. Angiotensin II stimulates two myelin basic protein/microtubule-associated protein 2 kinases in cultured vascular smooth muscle cells. Circ. Res. 71: 620-630, 1992[Abstract/Free Full Text].

57.   Tsuda, T., Y. Kawahara, K. Shii, M. Koide, Y. Ishida, and M. Yokoyama. Vasoconstrictor-induced protein-tyrosine phosphorylation in cultured vascular smooth muscle cells. FEBS Lett. 285: 44-48, 1991[Medline].

58.   Turner, C. E., K. M. Pietras, D. S. Taylor, and C. J. Molloy. Angiotensin II stimulation of rapid paxillin tyrosine phosphorylation correlates with the formation of focal adhesions in rat aortic smooth muscle cells. J. Cell Sci. 108: 333-342, 1995[Abstract].

59.   Uehara, Y., H. Fukazawa, Y. Murakami, and S. Mizuno. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem. Biophys. Res. Commun. 163: 803-809, 1989[Medline].

60.   Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269: 5241-5248, 1994[Abstract/Free Full Text].

Am J Physiol Heart Circ Physiol 276(6):H1927-H1934
0002-9513/99 $5.00 Copyright © 1999 the American Physiological Society


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. Gul, S.-Y. Kim, K.-H. Park, B.-J. Kim, S.-J. Kim, M.-J. Im, and U.-H. Kim
A novel signaling pathway of ADP-ribosyl cyclase activation by angiotensin II in adult rat cardiomyocytes
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H77 - H88.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. M. de Resende and A. S. Greene
Effect of ANG II on endothelial cell apoptosis and survival and its impact on skeletal muscle angiogenesis after electrical stimulation
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2814 - H2821.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
E. Mendez-Bolaina, J. Sanchez-Gonzalez, I. Ramirez-Sanchez, E. Ocharan-Hernandez, M. Nunez-Sanchez, E. Meaney-Mendiolea, A. Meaney, J. Asbun-Bojalil, A. Miliar-Garcia, I. Olivares-Corichi, et al.
Effect of caveolin-1 scaffolding peptide and 17 -estradiol on intracellular Ca2+ kinetics evoked by angiotensin II in human vascular smooth muscle cells
Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1953 - C1961.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
E. A. Woolfolk, S. Eguchi, H. Ohtsu, H. Nakashima, H. Ueno, W. T. Gerthoffer, and E. D. Motley
Angiotensin II-induced activation of p21-activated kinase 1 requires Ca2+ and protein kinase C{delta} in vascular smooth muscle cells
Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1286 - C1294.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
F. Li and K. U. Malik
Angiotensin II-induced Akt activation is mediated by metabolites of arachidonic acid generated by CaMKII-stimulated Ca2+-dependent phospholipase A2
Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2306 - H2316.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. Komers and S. Anderson
Paradoxes of nitric oxide in the diabetic kidney
Am J Physiol Renal Physiol, June 1, 2003; 284(6): F1121 - F1137.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Berry, R. Touyz, A. F. Dominiczak, R. C. Webb, and D. G. Johns
Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide
Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2337 - H2365.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Katoh, K. Egashira, C. Kataoka, M. Usui, M. Koyanagi, S. Kitamoto, Y. Ohmachi, A. Takeshita, and H. Narita
Regression by ACE inhibition of arteriosclerotic changes induced by chronic blockade of NO synthesis in rats
Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H2306 - H2312.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. Hiraoka, S. Kawashima, T. Takahashi, Y. Rikitake, T. Kitamura, W. Ogawa, and M. Yokoyama
TNF-{alpha} induces protein synthesis through PI3-kinase-Akt/PKB pathway in cardiac myocytes
Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1861 - H1868.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
R. M. Touyz and E. L. Schiffrin
Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells
Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and Th. Unger
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
Pharmacol. Rev., September 1, 2000; 52(3): 415 - 472.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. Haendeler, M. Ishida, L. Hunyady, and B. C. Berk
The Third Cytoplasmic Loop of the Angiotensin II Type 1 Receptor Exerts Differential Effects on Extracellular Signal-Regulated Kinase (ERK1/ERK2) and Apoptosis via Ras- and Rap1-Dependent Pathways
Circ. Res., April 14, 2000; 86(7): 729 - 736.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. N. Muller, R. Dechend, E. M. A. Mervaala, J.-K. Park, F. Schmidt, A. Fiebeler, J. Theuer, V. Breu, D. Ganten, H. Haller, et al.
NF-{kappa}B Inhibition Ameliorates Angiotensin II-Induced Inflammatory Damage in Rats
Hypertension, January 1, 2000; 35(1): 193 - 201.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, T.
Right arrow Articles by Yokoyama, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, T.
Right arrow Articles by Yokoyama, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online